Neuland Laboratories Ltd Stock Price Today (NSE: NEULANDLAB)
Fundamental Score
Neuland Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Neuland Laboratories Ltd share price today is ₹13669.00, up +0.00% on NSE/BSE as of 17 February 2026. Neuland Laboratories Ltd (NEULANDLAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.22K (Cr). The 52-week high for NEULANDLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 108.36x, NEULANDLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.83% and a debt-to-equity ratio of 0.16.
Neuland Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Neuland Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Neuland Laboratories Share Price
The pharmaceutical industry, often characterized by long research and development cycles and stringent regulatory approvals, demands a keen focus on innovation and efficiency to maintain profitability. This analysis delves into the financial health of Neuland Laboratories Ltd, focusing on key metrics that influence the Neuland Laboratories share price. As of the latest data, the share price stands at ₹13030.0, accompanied by a Price-to-Earnings (PE) ratio of 108.36 and a Return on Capital Employed (ROCE) of 18.66%.
The elevated PE ratio of 108.36 suggests that the market has high expectations for Neuland Laboratories' future earnings growth. While a high PE can indicate optimism, it also implies increased risk, as the company needs to justify this valuation with substantial growth. In contrast, comparing Neuland Laboratories Ltd with peers like
Mankind Pharma Ltd in the pharmaceutical sector, especially concerning management quality and strategic decision-making, could provide further insights into the sustainability of this growth trajectory. How effectively the company navigates regulatory hurdles and capitalizes on market opportunities will be crucial in validating its current valuation.A critical indicator of financial health is the Return on Capital Employed (ROCE), which currently sits at 18.66%. This metric reflects how efficiently the company is utilizing its capital to generate profits. A consistently high ROCE, like the one Neuland Laboratories demonstrates, indicates a strong moat. The moat, in this context, can be seen as the company's ability to maintain its competitive advantage and generate superior returns over its competitors. This ROCE potentially enables further investment in research and development or strategic acquisitions, strengthening its market position. However, sustaining this level of return requires continuous innovation and operational efficiency.
This financial analysis is based on publicly available data and forms part of a comprehensive 80-parameter fundamental audit of Neuland Laboratories. The audit process has been verified by Sweta Mishra to ensure accuracy and completeness. The analysis is purely observational and does not constitute investment advice. It is crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Neuland Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NEULANDLAB across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Excellent ROCE Performance (18.66%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (22.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (194.91%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (65.45%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.13% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (66.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (66.88% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.16)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (18.79x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹450.53 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 34.15%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 108.36x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Neuland Laboratories Ltd Financial Statements
Comprehensive financial data for Neuland Laboratories Ltd including income statement, balance sheet and cash flow
About NEULANDLAB (Neuland Laboratories Ltd)
Neuland Laboratories Ltd (NEULANDLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹21.22K (Cr). Neuland Laboratories Ltd has delivered a Return on Equity (ROE) of 14.83% and a ROCE of 18.66%. The debt-to-equity ratio stands at 0.16, reflecting the company's capital structure. Investors tracking NEULANDLAB share price can monitor key metrics including P/E ratio, promoter holding of 32.64%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
NEULANDLAB Share Price: Frequently Asked Questions
What is the current share price of Neuland Laboratories Ltd (NEULANDLAB)?
As of 17 Feb 2026, 10:17 am IST, Neuland Laboratories Ltd share price is ₹13669.00. The NEULANDLAB stock has a market capitalisation of ₹21.22K (Cr) on NSE/BSE.
Is NEULANDLAB share price Overvalued or Undervalued?
NEULANDLAB share price is currently trading at a P/E ratio of 108.36x, compared to the industry average of 31.77x. Based on this relative valuation, the Neuland Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of NEULANDLAB share price?
The 52-week high of NEULANDLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Neuland Laboratories Ltd share price?
Key factors influencing NEULANDLAB share price include quarterly earnings growth (Sales Growth: 65.45%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Neuland Laboratories Ltd a good stock for long-term investment?
Neuland Laboratories Ltd shows a 5-year Profit Growth of 66.88% and an ROE of 14.83%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.16 before investing in NEULANDLAB shares.
How does Neuland Laboratories Ltd compare with its industry peers?
Neuland Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare NEULANDLAB share price P/E of 108.36x and ROE of 14.83% against the industry averages to determine competitive standing.
What is the P/E ratio of NEULANDLAB and what does it mean?
NEULANDLAB share price has a P/E ratio of 108.36x compared to the industry average of 31.77x. Investors pay ₹108 for every ₹1 of annual earnings.
How is NEULANDLAB performing according to Bull Run's analysis?
NEULANDLAB has a Bull Run fundamental score of 63/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NEULANDLAB belong to?
NEULANDLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Neuland Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for NEULANDLAB?
NEULANDLAB has an ROE of 14.83%, which shows decent profitability but room for improvement. ROE measures how efficiently Neuland Laboratories Ltd generates profits from shareholders capital.
How is NEULANDLAB debt-to-equity ratio and what does it indicate?
NEULANDLAB has a debt-to-equity ratio of 0.16, which indicates conservative financing with low financial risk.
What is NEULANDLAB dividend yield and is it a good dividend stock?
NEULANDLAB offers a dividend yield of 0.07%, meaning you receive ₹0.07 annual dividend for every ₹100 invested in Neuland Laboratories Ltd shares.
How has NEULANDLAB share price grown over the past 5 years?
NEULANDLAB has achieved 5-year growth rates of: Sales Growth 14.13%, Profit Growth 66.88%, and EPS Growth 66.88%.
What is the promoter holding in NEULANDLAB and why does it matter?
Promoters hold 32.64% of NEULANDLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Neuland Laboratories Ltd.
What is NEULANDLAB market capitalisation category?
NEULANDLAB has a market capitalisation of ₹21216 crores, placing it in the Large-cap category.
How volatile is NEULANDLAB stock?
NEULANDLAB has a beta of N/A. A beta > 1 suggests the Neuland Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NEULANDLAB operating profit margin trend?
NEULANDLAB has a 5-year average Operating Profit Margin (OPM) of 22.21%, indicating the company's operational efficiency.
How is NEULANDLAB quarterly performance?
Recent quarterly performance shows Neuland Laboratories Ltd YoY Sales Growth of 65.45% and YoY Profit Growth of 194.91%.
What is the institutional holding pattern in NEULANDLAB?
NEULANDLAB has FII holding of 20.60% and DII holding of 13.55%. Significant institutional holding often suggests professional confidence in the Neuland Laboratories Ltd stock.